Cargando…
P866: IDECABTAGENE VICLEUCEL (IDE-CEL) VS STANDARD REGIMENS IN PATIENTS WITH TRIPLE-CLASS–EXPOSED (TCE) RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM): KARMMA-3 SUBGROUP ANALYSIS BY PRIOR LINES OF THERAPY
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431101/ http://dx.doi.org/10.1097/01.HS9.0000970368.33859.48 |
| _version_ | 1785091119986507776 |
|---|---|
| author | Manier, Salomon Rodríguez-Otero, Paula Mateos, Maria-Victoria Einsele, Hermann Bahlis, Nizar J Munshi, Nikhil Ailawadhi, Sikander Arnulf, Bertrand Nooka, Ajay Vij, Ravi Weum Abrahamsen, Ingerid Broijl, Annemiek Jagannath, Sundar Benjamin, Reuben Gergis, Usama Sborov, Douglas W. Iida, Shinsuke Truppel-Hartmann, Anna Yang, Zhihong Piasecki, Julia Felten, Jasper Caia, Andrea Cook, Mark Baz, Rachid |
| author_facet | Manier, Salomon Rodríguez-Otero, Paula Mateos, Maria-Victoria Einsele, Hermann Bahlis, Nizar J Munshi, Nikhil Ailawadhi, Sikander Arnulf, Bertrand Nooka, Ajay Vij, Ravi Weum Abrahamsen, Ingerid Broijl, Annemiek Jagannath, Sundar Benjamin, Reuben Gergis, Usama Sborov, Douglas W. Iida, Shinsuke Truppel-Hartmann, Anna Yang, Zhihong Piasecki, Julia Felten, Jasper Caia, Andrea Cook, Mark Baz, Rachid |
| author_sort | Manier, Salomon |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10431101 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104311012023-08-17 P866: IDECABTAGENE VICLEUCEL (IDE-CEL) VS STANDARD REGIMENS IN PATIENTS WITH TRIPLE-CLASS–EXPOSED (TCE) RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM): KARMMA-3 SUBGROUP ANALYSIS BY PRIOR LINES OF THERAPY Manier, Salomon Rodríguez-Otero, Paula Mateos, Maria-Victoria Einsele, Hermann Bahlis, Nizar J Munshi, Nikhil Ailawadhi, Sikander Arnulf, Bertrand Nooka, Ajay Vij, Ravi Weum Abrahamsen, Ingerid Broijl, Annemiek Jagannath, Sundar Benjamin, Reuben Gergis, Usama Sborov, Douglas W. Iida, Shinsuke Truppel-Hartmann, Anna Yang, Zhihong Piasecki, Julia Felten, Jasper Caia, Andrea Cook, Mark Baz, Rachid Hemasphere Posters Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10431101/ http://dx.doi.org/10.1097/01.HS9.0000970368.33859.48 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Manier, Salomon Rodríguez-Otero, Paula Mateos, Maria-Victoria Einsele, Hermann Bahlis, Nizar J Munshi, Nikhil Ailawadhi, Sikander Arnulf, Bertrand Nooka, Ajay Vij, Ravi Weum Abrahamsen, Ingerid Broijl, Annemiek Jagannath, Sundar Benjamin, Reuben Gergis, Usama Sborov, Douglas W. Iida, Shinsuke Truppel-Hartmann, Anna Yang, Zhihong Piasecki, Julia Felten, Jasper Caia, Andrea Cook, Mark Baz, Rachid P866: IDECABTAGENE VICLEUCEL (IDE-CEL) VS STANDARD REGIMENS IN PATIENTS WITH TRIPLE-CLASS–EXPOSED (TCE) RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM): KARMMA-3 SUBGROUP ANALYSIS BY PRIOR LINES OF THERAPY |
| title | P866: IDECABTAGENE VICLEUCEL (IDE-CEL) VS STANDARD REGIMENS IN PATIENTS WITH TRIPLE-CLASS–EXPOSED (TCE) RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM): KARMMA-3 SUBGROUP ANALYSIS BY PRIOR LINES OF THERAPY |
| title_full | P866: IDECABTAGENE VICLEUCEL (IDE-CEL) VS STANDARD REGIMENS IN PATIENTS WITH TRIPLE-CLASS–EXPOSED (TCE) RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM): KARMMA-3 SUBGROUP ANALYSIS BY PRIOR LINES OF THERAPY |
| title_fullStr | P866: IDECABTAGENE VICLEUCEL (IDE-CEL) VS STANDARD REGIMENS IN PATIENTS WITH TRIPLE-CLASS–EXPOSED (TCE) RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM): KARMMA-3 SUBGROUP ANALYSIS BY PRIOR LINES OF THERAPY |
| title_full_unstemmed | P866: IDECABTAGENE VICLEUCEL (IDE-CEL) VS STANDARD REGIMENS IN PATIENTS WITH TRIPLE-CLASS–EXPOSED (TCE) RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM): KARMMA-3 SUBGROUP ANALYSIS BY PRIOR LINES OF THERAPY |
| title_short | P866: IDECABTAGENE VICLEUCEL (IDE-CEL) VS STANDARD REGIMENS IN PATIENTS WITH TRIPLE-CLASS–EXPOSED (TCE) RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM): KARMMA-3 SUBGROUP ANALYSIS BY PRIOR LINES OF THERAPY |
| title_sort | p866: idecabtagene vicleucel (ide-cel) vs standard regimens in patients with triple-class–exposed (tce) relapsed and refractory multiple myeloma (rrmm): karmma-3 subgroup analysis by prior lines of therapy |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431101/ http://dx.doi.org/10.1097/01.HS9.0000970368.33859.48 |
| work_keys_str_mv | AT maniersalomon p866idecabtagenevicleucelidecelvsstandardregimensinpatientswithtripleclassexposedtcerelapsedandrefractorymultiplemyelomarrmmkarmma3subgroupanalysisbypriorlinesoftherapy AT rodriguezoteropaula p866idecabtagenevicleucelidecelvsstandardregimensinpatientswithtripleclassexposedtcerelapsedandrefractorymultiplemyelomarrmmkarmma3subgroupanalysisbypriorlinesoftherapy AT mateosmariavictoria p866idecabtagenevicleucelidecelvsstandardregimensinpatientswithtripleclassexposedtcerelapsedandrefractorymultiplemyelomarrmmkarmma3subgroupanalysisbypriorlinesoftherapy AT einselehermann p866idecabtagenevicleucelidecelvsstandardregimensinpatientswithtripleclassexposedtcerelapsedandrefractorymultiplemyelomarrmmkarmma3subgroupanalysisbypriorlinesoftherapy AT bahlisnizarj p866idecabtagenevicleucelidecelvsstandardregimensinpatientswithtripleclassexposedtcerelapsedandrefractorymultiplemyelomarrmmkarmma3subgroupanalysisbypriorlinesoftherapy AT munshinikhil p866idecabtagenevicleucelidecelvsstandardregimensinpatientswithtripleclassexposedtcerelapsedandrefractorymultiplemyelomarrmmkarmma3subgroupanalysisbypriorlinesoftherapy AT ailawadhisikander p866idecabtagenevicleucelidecelvsstandardregimensinpatientswithtripleclassexposedtcerelapsedandrefractorymultiplemyelomarrmmkarmma3subgroupanalysisbypriorlinesoftherapy AT arnulfbertrand p866idecabtagenevicleucelidecelvsstandardregimensinpatientswithtripleclassexposedtcerelapsedandrefractorymultiplemyelomarrmmkarmma3subgroupanalysisbypriorlinesoftherapy AT nookaajay p866idecabtagenevicleucelidecelvsstandardregimensinpatientswithtripleclassexposedtcerelapsedandrefractorymultiplemyelomarrmmkarmma3subgroupanalysisbypriorlinesoftherapy AT vijravi p866idecabtagenevicleucelidecelvsstandardregimensinpatientswithtripleclassexposedtcerelapsedandrefractorymultiplemyelomarrmmkarmma3subgroupanalysisbypriorlinesoftherapy AT weumabrahamseningerid p866idecabtagenevicleucelidecelvsstandardregimensinpatientswithtripleclassexposedtcerelapsedandrefractorymultiplemyelomarrmmkarmma3subgroupanalysisbypriorlinesoftherapy AT broijlannemiek p866idecabtagenevicleucelidecelvsstandardregimensinpatientswithtripleclassexposedtcerelapsedandrefractorymultiplemyelomarrmmkarmma3subgroupanalysisbypriorlinesoftherapy AT jagannathsundar p866idecabtagenevicleucelidecelvsstandardregimensinpatientswithtripleclassexposedtcerelapsedandrefractorymultiplemyelomarrmmkarmma3subgroupanalysisbypriorlinesoftherapy AT benjaminreuben p866idecabtagenevicleucelidecelvsstandardregimensinpatientswithtripleclassexposedtcerelapsedandrefractorymultiplemyelomarrmmkarmma3subgroupanalysisbypriorlinesoftherapy AT gergisusama p866idecabtagenevicleucelidecelvsstandardregimensinpatientswithtripleclassexposedtcerelapsedandrefractorymultiplemyelomarrmmkarmma3subgroupanalysisbypriorlinesoftherapy AT sborovdouglasw p866idecabtagenevicleucelidecelvsstandardregimensinpatientswithtripleclassexposedtcerelapsedandrefractorymultiplemyelomarrmmkarmma3subgroupanalysisbypriorlinesoftherapy AT iidashinsuke p866idecabtagenevicleucelidecelvsstandardregimensinpatientswithtripleclassexposedtcerelapsedandrefractorymultiplemyelomarrmmkarmma3subgroupanalysisbypriorlinesoftherapy AT truppelhartmannanna p866idecabtagenevicleucelidecelvsstandardregimensinpatientswithtripleclassexposedtcerelapsedandrefractorymultiplemyelomarrmmkarmma3subgroupanalysisbypriorlinesoftherapy AT yangzhihong p866idecabtagenevicleucelidecelvsstandardregimensinpatientswithtripleclassexposedtcerelapsedandrefractorymultiplemyelomarrmmkarmma3subgroupanalysisbypriorlinesoftherapy AT piaseckijulia p866idecabtagenevicleucelidecelvsstandardregimensinpatientswithtripleclassexposedtcerelapsedandrefractorymultiplemyelomarrmmkarmma3subgroupanalysisbypriorlinesoftherapy AT feltenjasper p866idecabtagenevicleucelidecelvsstandardregimensinpatientswithtripleclassexposedtcerelapsedandrefractorymultiplemyelomarrmmkarmma3subgroupanalysisbypriorlinesoftherapy AT caiaandrea p866idecabtagenevicleucelidecelvsstandardregimensinpatientswithtripleclassexposedtcerelapsedandrefractorymultiplemyelomarrmmkarmma3subgroupanalysisbypriorlinesoftherapy AT cookmark p866idecabtagenevicleucelidecelvsstandardregimensinpatientswithtripleclassexposedtcerelapsedandrefractorymultiplemyelomarrmmkarmma3subgroupanalysisbypriorlinesoftherapy AT bazrachid p866idecabtagenevicleucelidecelvsstandardregimensinpatientswithtripleclassexposedtcerelapsedandrefractorymultiplemyelomarrmmkarmma3subgroupanalysisbypriorlinesoftherapy |